Role of p38-mitogen-activated protein kinase in ischaemic preconditioning in rat heart

Clinical and Experimental Pharmacology and Physiology

Volumn 35, Issue 2, 2008, Pages 126-134

  Bell, James R ^a   Eaton, Philip ^a   Shattock, Michael J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Ischaemia; Protein kinases; Reperfusion; Signal transduction

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ALPHA CRYSTALLIN; BETA CRYSTALLIN; DIMETHYL SULFOXIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; TETRAZOLIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; ISCHEMIC PRECONDITIONING; MALE; NONHUMAN; RAT;

ALPHA-CRYSTALLIN B CHAIN; ANIMALS; ANTIOXIDANTS; CELL SURVIVAL; DIMETHYL SULFOXIDE; ENZYME ACTIVATION; IMIDAZOLES; ISCHEMIA; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MYOCARDIAL CONTRACTION; MYOCARDIUM; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PERFUSION; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIDINES; RATS; RATS, WISTAR; REPRODUCIBILITY OF RESULTS; SOLVENTS; TIME FACTORS;

EID: 38149108156     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2007.04794.x     Document Type: Article

References (57)

1. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 1986 74: 1124 36.
2. Goto M, Liu Y, Yang XM, Ardell JL, Cohen MV, Downey JM. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ. Res. 1995 77: 611 21.
3. Liu GS, Thornton J, Van Winkle DM, Stanley AW, Olsson RA, Downey JM. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation 1991 84: 350 6.
4. Schultz JE, Hsu AK, Gross GJ. Ischemic preconditioning in the intact rat heart is mediated by delta1- but not mu- or kappa-opioid receptors. Circulation 1998 97: 1282 9.
5. Ytrehus K, Liu Y, Downey JM. Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am. J. Physiol. 1994 266: H1145 52.
6. Armstrong SC, Hoover DB, Delacey MH, Ganote CE. Translocation of PKC, protein phosphatase inhibition and preconditioning of rabbit cardiomyocytes. J. Mol. Cell. Cardiol. 1996 28: 1479 92.
7. Weinbrenner C, Liu G-S, Cohen MV, Downey JM. Phosphorylation of tyrosine 182 of p38 mitogen-activated protein kinase correlates with the protection of preconditioning in the rabbit heart. J. Mol. Cell. Cardiol. 1997 29: 2383 91.
8. Mocanu MM, Baxter GF, Yue Y, Critz SD, Yellon DM. The p38 inhibitor, SB203580, abrogates ischaemic preconditioning in rat heart but timing of administration is critical. Basic Res. Cardiol. 2000 95: 472 8.
9. Nakano A, Baines CP, Kim SO et al. Ischemic preconditioning activates MAPKAPK2 in the isolated rabbit heart. Circ. Res. 2000 86: 144 51.
10. Yue Y, Krenz M, Cohen MV, Downey JM, Critz SD. Menadione mimics the infarct-limiting effect of preconditioning in isolated rat hearts. Am. J. Physiol. Heart Circ. Physiol. 2001 281: H590 5.
11. Baines CP, Goto M, Downey JM. Oxygen radicals released during ischemic preconditioning contribute to cardioprotection in the rabbit myocardium. J. Mol. Cell. Cardiol. 1997 29: 207 16.
12. Oldenburg O, Qin Q, Krieg T et al. Bradykinin induces mitochondrial ROS generation via NO, cGMP, PKG, and mitoKATP channel opening and leads to cardioprotection. Am. J. Physiol. Heart Circ. Physiol. 2004 286: H468 76.
13. Han J, Lee JD, Bibbs L, Ulevitch RJ. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994 265: 808 11.
14. Paul A, Wilson S, Belham CM et al. Stress-activated protein kinases: Activation, regulation and function. Cell Signal. 1997 9: 403 10.
15. Dong C, Davis RJ, Flavell RA. MAP kinases in the immune response. Annu. Rev. Immunol. 2002 20: 55 72.
16. Clerk A, Fuller SJ, Michael A, Sugden PH. Stimulation of 'stress-regulated' mitogen-activated protein kinases (stress-activated protein kinases/c-Jun N-terminal kinases and p38-mitogen-activated protein kinases) in perfused rat hearts by oxidative and other stresses. J. Biol. Chem. 1998 273: 7228 34.
17. Bogoyevitch MA, Gillespie-Brown J, Ketterman AJ et al. Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart; p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischaemia/reperfusion. Circ. Res. 1996 79: 162 73.
18. Yin T, Sandhu G, Wolfgang CD et al. Tissue-specific pattern of stress kinase activation in ischemic/reperfused heart and kidney. J. Biol. Chem. 1997 272: 19 943 50.
19. Shimizu N, Yoshiyama M, Omura T et al. Activation of mitogen-activated protein kinases and activator protein-1 in myocardial infarction in rats. Cardiovasc. Res. 1998 38: 116 24.
20. Mackay K, Mochly-Rosen D. An inhibitor of p38 mitogen-activated protein kinase protects neonatal cardiac myocytes from ischaemia. J. Biol. Chem. 1999 274: 6272 9.
21. Ma XL, Kumar S, Gao F et al. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation 1999 99: 1685 91.
22. Barancik M, Htun P, Strohm C, Kilian S, Schaper W. Inhibition of the cardiac p38-MAPK pathway by SB203580 delays ischemic cell death. J. Cardiovasc. Pharmacol. 2000 35: 474 83.
23. Tanno M, Bassi R, Gorog DA et al. Diverse mechanisms of myocardial p38 mitogen-activated protein kinase activation: Evidence for MKK-independent activation by a TAB1-associated mechanism contributing to injury during myocardial ischemia. Circ. Res. 2003 93: 254 61.
24. Schneider S, Chen W, Hou J, Steenbergen C, Murphy E. Inhibition of p38 MAPK α/β reduces ischemic injury and does not block protective effects of preconditioning. Am. J. Physiol. Heart Circ. Physiol. 2001 280: H499 508.
25. Marais E, Genade S, Huisamen B, Strijdom JG, Moolman JA, Lochner A. Activation of p38 MAPK induced by a multi-cycle ischaemic preconditioning protocol is associated with attenuated p38 MAPK activity during sustained ischaemia and reperfusion. J. Mol. Cell. Cardiol. 2001 33: 769 78.
26. Eaton P, Fuller W, Bell JR, Shattock MJ. Alpha B crystallin translocation and phosphorylation: Signal transduction pathways and preconditioning in the isolated rat heart. J. Mol. Cell. Cardiol. 2001 33: 1659 71.
27. Gysembergh A, Simkhovich BZ, Kloner RA, Przyklenk K. p38 MAPK activity is not increased early during sustained coronary artery occlusion in preconditioned versus control rabbit heart. J. Mol. Cell. Cardiol. 2001 33: 681 90.
28. Fryer RM, Patel HH, Hsu AK, Gross GJ. Stress-activated protein kinase phosphorylation during cardioprotection in the ischemic myocardium. Am. J. Physiol. Heart Circ. Physiol. 2001 281: H1184 92.
29. Sanada S, Kitakaze M, Papst PJ et al. Role of phasic dynamism of p38 mitogen-activated protein kinase activation in ischemic preconditioning of the canine heart. Circ. Res. 2001 88: 175 80.
30. Saurin AT, Martin JL, Heads RJ et al. The role of differential activation of p38-mitogen-activated protein kinase in preconditioned ventricular myocytes. FASEB J. 2001 14: 2237 46.
31. Yue T, Wang C, Gu J et al. Inhibition of extracellular signal-regulated kinase enhances ischemia/reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart. Circ. Res. 2000 86: 692 9.
32. Armstrong SC, Delacey M, Ganote CE. Phosphorylation state of hsp27 and p38 MAPK during preconditioning and protein phosphatase inhibitor protection of rabbit cardiomyocytes. J. Mol. Cell. Cardiol. 1999 31: 555 67.
33. Young PR, McLaughlin MM, Kumar S et al. Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J. Biol. Chem. 1997 272: 12 116 21.
34. Sato M, Cordis GA, Maulik N, Das DK. SAPKs regulation of ischemic preconditioning. Am. J. Physiol. Heart Circ. Physiol. 2000 279: H901 7.
35. Nakano A, Cohen MV, Critz S, Downey JM. SB 203580, an inhibitor of p38 MAPK, abolishes infarct-limiting effect of ischemic preconditioning in isolated rabbit hearts. Basic Res. Cardiol. 2000 95: 466 71.
36. Tanaka M, Fujiwara H, Yamasaki K, Sasayama S. Superoxide dismutase and N-2-mercaptopropionyl glycine attenuate infarct size limitation effect of ischaemic preconditioning in the rabbit. Cardiovasc. Res. 1994 28: 980 6.
37. Yao Z, Tong J, Tan X et al. Role of reactive oxygen species in acetylcholine-induced preconditioning in cardiomyocytes. Am. J. Physiol. 1999 277: H2504 9.
38. Santos NC, Figueira-Coelho J, Martins-Silva J, Saldanha C. Multidisciplinary utilization of dimethyl sulfoxide: Pharmacological, cellular, and molecular aspects. Biochem. Pharmacol. 2003 65: 1035 41.
39. Hoover HE, Thuerauf DJ, Martindale JJ, Glembotski CC. Alpha B-crystallin gene induction and phosphorylation by MKK6-activated p38. A potential role for alpha B-crystallin as a target of the p38 branch of the cardiac stress response. J. Biol. Chem. 2000 275: 23 825 33.
40. Kolocassides KG, Galinanes M, Hearse DJ. Dichotomy of ischemic preconditioning: Improved post-ischemic contractile function despite intensification of ischemic contracture. Circulation 1996 93: 1725 33.
41. Galinanes M, Wilson ANA, Hearse DJ. Impaired cardioplegic delivery and the loss of cardioprotection: A role for preconditioning. J. Mol. Cell. Cardiol. 1997 29: 849 54.
42. Garlick PB, Davies MJ, Hearse DJ, Slater TF. Direct detection of free radicals in the reperfused rat heart using electron spin resonance spectroscopy. Circ. Res. 1987 61: 757 60.
43. Zweier JL, Flaherty JT, Weisfeldt ML. Direct measurement of free radical generation following reperfusion of ischemic myocardium. Proc. Natl Acad. Sci. USA 1987 84: 1404 7.
44. Bolli R, Patel BS, Jeroudi MO, Lai EK, McCay PB. Demonstration of free radical generation in 'stunned' myocardium of intact dogs with the use of the spin trap alpha-phenyl N-tert-butyl nitrone. J. Clin. Invest. 1988 82: 476 85.
45. Horwitz LD, Fennessey PV, Shikes RH, Kong Y. Marked reduction in myocardial infarct size due to prolonged infusion of an antioxidant during reperfusion. Circulation 1994 89: 1792 801.
46. Werns SW, Simpson PJ, Mickelson JK, Shea MJ, Pitt B, Lucchesi BR. Sustained limitation by superoxide dismutase of canine myocardial injury due to regional ischemia followed by reperfusion. J. Cardiovasc. Pharmacol. 1988 11: 36 44.
47. Shlafer M. Cardiac pharmacology of dimethyl sulfoxide and its postulated relevance to organ preservation in ischemic or hypoxic states. Ann. N.Y. Acad. Sci. 1983 411: 170 9.
48. Ogura T, Kasamaki Y, McDonald TF. Force-relaxant actions of dimethyl sulfoxide on guinea-pig and rabbit papillary muscles. J. Mol. Cell. Cardiol. 1996 28: 1777 88.
49. Falck G, Schjott J, Jynge P. Hyperosmotic pretreatment reduces infarct size in the rat heart. Physiol. Res. 1999 48: 331 40.
50. Diaz RJ, Mao GD, Losito VA, Backx PH, Wilson GJ. Hypo-osmotic stress and ischemic preconditioning share cellular signalling pathways in producing protection in ventricular myocytes. Circulation 1999 100 (Suppl 2972 (Abstract).
51. Lali FV, Hunt AE, Turner SJ, Foxwell BMJ. The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phosphorylation, and retinoblastoma hyperphosphorylation in interleukin-2-stimulated T cells independently of p38 mitogen-activated protein kinase. J. Biol. Chem. 2000 275: 7395 402.
52. Clerk A, Sugden PH. The p38-MAPK inhibitor, SB203580, inhibits cardiac stress-activated protein kinases/c-Jun N-terminal kinases (SAPKs/JNKs). FEBS Lett. 1998 426: 93 6.
53. Schulz R, Cohen MV, Behrends M, Downey JM, Heusch G. Signal transduction of ischemic preconditioning. Cardiovasc. Res. 2001 52: 181 98.
54. Das DK, Engelman RM, Kimura Y. Molecular adaptation of cellular defences following preconditioning of the heart by repeated ischemia. Cardiovasc. Res. 1993 27: 578 84.
55. Ghosh S, Standen NB, Galinanes M. Preconditioning the human myocardium by simulated ischemia: Studies on the early and delayed protection. Cardiovasc. Res. 2000 45: 339 50.
56. Ghosh S, Standen NB, Galinanes M. Failure to precondition pathological human myocardium. J. Am. Coll. Cardiol. 2001 37: 711 18.
57. Bolli R, Marban E. Molecular and cellular mechanisms of myocardial stunning. Physiol. Rev. 1999 79: 609 34.